Inventor · disambiguated record
Jinsheng Ren
Also filed as: REN JINSHENG
4 granted patents·36 pending applications·1 citations·filing 2010–2025
59Inventor score
Files withSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD8SIMCERE ZAIMING PHARMACEUTICAL CO LTD7JIANGSU SIMCERE PHARM CO LTD6HAINAN SIMCERE PHARMACEUTICAL CO LTD4NANJING ZAIMING PHARMACEUTICAL CO LTD4
Top patents by PatentIndex Score
40 records- 0177US12319725B2IL-2 mutant and application thereofHAINAN SIMCERE PHARMACEUTICAL CO LTD·Filed 2024·Granted Jun 3, 2025·0 cites·16 claims
- 0275US2025382343A1Il-2 Mutants And Uses ThereofHAINAN SIMCERE PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 0372US2024209051A1Il-2 Mutant And Application ThereofHAINAN SIMCERE PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0465US12421286B2Il-2 mutant and application thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2021·Granted Sep 23, 2025·0 cites·14 claims
- 0559US2025122221A1Six-membered cyclothiazole compound and use thereofNANJING ZAIMING PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0655US9209444B2Polymide blend nanofiber and its use in battery separatorHOU HAOQING·Filed 2010·Granted Dec 8, 2015·1 cites·9 claims
- 0754US2025270227A1Camptothecin derivative, and pharmaceutical composition and use thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0853US2024124454A1Tricyclic compound and use thereofNANJING ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 0953US2025009847A1Il-15 mutant fusion protein pharmaceutical compositionSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1053US2025186550A1Pharmaceutical composition of il2 mutant-antibody fc block fusion protein and use thereofHAINAN SIMCERE PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1151US2024343803A1Anti-Pvrig/Anti-Tigit Bispecific Antibodies And Applications ThereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1251US2024124575A1Human cd33 antibody and use thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1350US2025075006A1Anti-gucy2c nano-antibody and application thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1450US2024307415A1Steroid compound, and pharmaceutical composition thereof and use thereofJIANGSU SIMCERE PHARM CO LTD·Filed 2022·Application pending·0 cites
- 1550US2025297021A1Bcma antibody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO NO 1·Filed 2022·Application pending·0 cites
- 1649US2024343811A1Cd16 antibody and use thereofSHANDONG SIMCERE BIOPHARMACUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1749US2025297030A1Anti-muc17 nanobody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1849US2025042994A1Cd19 antibody and application thereofHAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1949US2025145705A1Gprc5d antibody and application thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2048US12297284B2Anti-TNFR2 antibody and use thereofJIANGSU SIMCERE PHARM CO LTD·Filed 2020·Granted May 13, 2025·0 cites·12 claims
- 2148US2023002492A1Anti-human programmed cell death ligand-1 (pd-l1) antibody and use thereofSIMCERE SHANGHAI PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 2248US2024033247A1Use of composition in treatment of cerebral strokeSimcere pharmaceutical co ltd·Filed 2021·Application pending·0 cites
- 2348US2025136687A1Anti-human cd3 antibody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2447US2024084003A1Anti-human cd22 monoclonal antibodies and use thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2547US2025179172A1Cd5 antibody and use thereofHAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 2647US2024109974A1Humanized antibody against tnfr2 and use thereofJIANGSU SIMCERE PHARM CO LTD·Filed 2022·Application pending·0 cites
- 2746US2023293556A1Pharmaceutical composition of aquaporin inhibitor and preparation method thereofJIANGSU SIMCERE PHARM CO LTD·Filed 2021·Application pending·0 cites
- 2846US2023416360A1Anti-cd22 nano antibody and use thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 2946US2025250357A1Anti-msln antibody and application thereofNANJING ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3046US2025026844A1Anti-bcma nanobody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3145US2023250108A1Tetrahydroisoquinoline compounds and use thereofJIANGSU SIMCERE PHARM CO LTD·Filed 2021·Application pending·0 cites
- 3244US2023192797A1Human il-15 mutant and uses thereofJIANGSU SIMCERE PHARM CO LTD·Filed 2021·Application pending·0 cites
- 3344US2023142274A1Substituted aryl compoundSimcere pharmaceutical co ltd·Filed 2021·Application pending·0 cites
- 3443US2024076403A1Her2 antibody and application thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3543US2023364059A1Stable pharmaceutical compositionSimcere pharmaceutical co ltd·Filed 2021·Application pending·0 cites
- 3641US2024124563A1Anti-Human MSLN Antibody And Application ThereofNANJING ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3740US2024052055A1Gpc3 antibody and application thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3840US2024101686A1Anti-egfr nanobody and use thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3931US2014043727A1Polyimide Capacitance Battery and Manufacturing Method ThereofLV XIAOYI·Filed 2011·Application pending·0 cites
- 4026US2013196562A1Copolymide nano-fiber non-woven fabric, process for producing the same and the use thereofHOU HAOQING·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jinsheng Ren files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →